3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
High Risk Myeloid Malignancies
1
Interventions
Gemcitabine
57
130-nm albumin-bound paclitaxel
35
Specimen Handling
26
Magnetic Resonance Spectroscopy
21
Albumin-Bound Paclitaxel
21
Fluorouracil
20
Leucovorin
19
Irinotecan
19
Oxaliplatin
17
Biopsy
17
Taxes
16
pembrolizumab
13
Cyclophosphamide
11
Cisplatin
11
fludarabine
10
Cetuximab
9
Capecitabine
8
Nivolumab
7
Carboplatin
7
irinotecan sucrosofate
6
durvalumab
6
dehydroftorafur
6
Radiosurgery
6
Pemetrexed
6
olaparib
5
Ipilimumab
5
Erlotinib Hydrochloride
5
trastuzumab deruxtecan
4
aldesleukin
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Transplantation Conditioning
×
90 days
×
Clear all
NCT07627711
2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled
NCT07480928
2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled